X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DIVIS LABORATORIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DIVIS LABORATORIES CIPLA/
DIVIS LABORATORIES
 
P/E (TTM) x 40.6 38.4 105.8% View Chart
P/BV x 3.7 6.2 60.0% View Chart
Dividend Yield % 0.5 0.7 62.9%  

Financials

 CIPLA   DIVIS LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-18
DIVIS LABORATORIES
Mar-18
CIPLA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6631,142 58.1%   
Low Rs479533 89.9%   
Sales per share (Unadj.) Rs189.0146.6 129.0%  
Earnings per share (Unadj.) Rs17.633.0 53.3%  
Cash flow per share (Unadj.) Rs34.038.4 88.6%  
Dividends per share (Unadj.) Rs3.0010.00 30.0%  
Dividend yield (eoy) %0.51.2 44.0%  
Book value per share (Unadj.) Rs176.7222.8 79.3%  
Shares outstanding (eoy) m805.12265.47 303.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.7 52.9%   
Avg P/E ratio x32.525.3 128.0%  
P/CF ratio (eoy) x16.821.8 77.0%  
Price / Book Value ratio x3.23.8 86.0%  
Dividend payout %17.130.3 56.3%   
Avg Mkt Cap Rs m459,724222,318 206.8%   
No. of employees `00023.610.8 219.4%   
Total wages/salary Rs m26,9014,561 589.9%   
Avg. sales/employee Rs Th6,446.13,616.0 178.3%   
Avg. wages/employee Rs Th1,139.4423.8 268.9%   
Avg. net profit/employee Rs Th600.0814.9 73.6%   
INCOME DATA
Net Sales Rs m152,19338,915 391.1%  
Other income Rs m3,5771,134 315.3%   
Total revenues Rs m155,76940,049 388.9%   
Gross profit Rs m28,26412,617 224.0%  
Depreciation Rs m13,2281,425 928.4%   
Interest Rs m1,14213 8,588.7%   
Profit before tax Rs m17,47012,313 141.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5013,543 70.6%   
Profit after tax Rs m14,1668,770 161.5%  
Gross profit margin %18.632.4 57.3%  
Effective tax rate %14.328.8 49.8%   
Net profit margin %9.322.5 41.3%  
BALANCE SHEET DATA
Current assets Rs m108,14145,351 238.5%   
Current liabilities Rs m38,3226,507 588.9%   
Net working cap to sales %45.999.8 46.0%  
Current ratio x2.87.0 40.5%  
Inventory Days Days97127 76.6%  
Debtors Days Days7495 78.2%  
Net fixed assets Rs m109,41121,160 517.1%   
Share capital Rs m1,610531 303.3%   
"Free" reserves Rs m140,68258,625 240.0%   
Net worth Rs m142,29259,156 240.5%   
Long term debt Rs m36,6210-   
Total assets Rs m228,60667,832 337.0%  
Interest coverage x16.3926.8 1.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.6 116.0%   
Return on assets %6.712.9 51.7%  
Return on equity %10.014.8 67.2%  
Return on capital %10.020.8 47.8%  
Exports to sales %32.80-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m51,69132,359 159.7%   
Fx outflow Rs m21,0339,042 232.6%   
Net fx Rs m30,65823,317 131.5%   
CASH FLOW
From Operations Rs m14,6287,759 188.5%  
From Investments Rs m-8,540-4,783 178.6%  
From Financial Activity Rs m-3,855-3,142 122.7%  
Net Cashflow Rs m2,431-166 -1,464.5%  

Share Holding

Indian Promoters % 16.0 52.0 30.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.8 103.4%  
FIIs % 23.7 19.0 124.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.2 152.3%  
Shareholders   161,166 31,796 506.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WYETH LTD  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 21, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS